Tickers: XTSX:VPT, PINX:VPTDF
Tags: Heathcare, Technology
Toronto / TheNewswire / November 20, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT, OTCQB:VPTDF) is pleased to announce that Dr. Kai Thorsten Laser, an internationally renowned pediatric cardiologist at the HDZ NRW Heart and Diabetes Center in Germany, has begun using VMS+ software for 3D Echo analysis of the left ventricle.
HDZ NRW, a hospital specializing in the treatment of cardiac, vascular and metabolic diseases has already implemented the VMS+ software for analysis of the right ventricle. Now that the software has been approved for all 4 chambers of the heart, the hospital will be using the Ventripoint VMS+ system for left ventricular volume analysis, particularly for their pediatric patients.
"We have experienced very positive results and accuracy using Ventripoint's VMS+ system on the right ventricle. We now look forward to performing 3D analysis to validate accuracy of volumes of the left ventricle and in turn, improve cardiac patient care." commented Dr. Kai Thorsten Laser, MD in the Department of Congenital Heart Defects, Heart and Diabetes Center.
There are many potential applications for this innovative technology; providing confidence in the volumetric measurements of patients with accuracy comparable to cardiac MRI is its strength.
About HDZ NRW Heart and Diabetes Center
Four clinics, three university institutes, plus other institutes and internal service providers affiliated to the HDZ NRW together make up a center of competence which is both a German national, and an international leader. The Heart and Diabetes Center NRW is setting new standards for the treatment of cardiac, vascular and diabetic diseases.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information, please contact:
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.
